Cytokinetics price to sales ratio CYTK

Market value divided by revenue over the last twelve months, since 2012.

Today, Oct 23, 2026: 126×
10-year median: 34.9×
Against its 10-year history: 91st; percentile: 0 is its lowest day, 100 its highest
10-year range: 4.5× to 197×
Peer median: 5.8×

Cytokinetics' price to sales ratio is 126× as of Oct 23, 2026.

That is above its ten-year median of 34.9×, higher than on 91% of days in the last ten years.

Over that time it ranged from 4.5× in Apr 2017 to 197× in May 2025.

The median for 10 large drugmakers of a similar size is 5.8×.

Price to sales ratio over time

median 34.9×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	126×	82.5×	158×
2025	88.5×	47.6×	197×
2024	n/m a value too high to mean anything
2023	32.4×	26.7×	42.2×
2022	29.3×	22.8×	157×
2021	177×	23.6×	177×
2020	27.1×	20.8×	91.8×
2019	n/m a value too high to mean anything
2018	9.9×	8.2×	11.4×
2017	9.4×	4.5×	14.5×
2016	5.9×	4.6×	15.2×
2015	10.0×	4.7×	11.5×
2014	4.5×	2.5×	35.5×
2013	23.3×	18.6×	58.8×
2012	15.3×	9.2×	19.6×

Against its peers

Companies in Drug Manufacturers - General nearest Cytokinetics' size, closest first, today.

Company	Price to sales ratio
CYTKCytokinetics	126×
TGTXTG Therapeutics	10.4×
PTGXProtagonist Therapeutics	31.8×
CORTCorcept Therapeutics	11.2×
ALKSAlkermes plc.	4.4×
BMRNBiomarin Pharmaceutical	3.2×
AMRXAmneal Pharmaceuticals	2.1×
LGNDLigand Pharmaceuticals	20.8×
KNSAKiniksa Pharmaceuticals International	7.1×
JAZZJazz Pharmaceuticals	3.0×
INDVIndivior Pharmaceuticals	3.1×
Peer median	5.8×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Cytokinetics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.